In Vitro Assessment of Cardiac Risk in Drug Discovery

Date: 
16 May

Opportunities to Leverage Non-clinical Data in a Regulatory Integrated QTc Assessment

Presented by: Derek Leishman, Vice President, Translational and Quantitative Toxicology, Eli Lilly and Company

A Clinically Translatable hIPSC Cardiomyocyte Model to Predict QTc and QRS Cardiac Risk

Presented by: Steve Jenkinson, Vice President, Drug Discovery and Safety, Metrion Biosciences

Venue and Location Information: 
Webinar